Expert gps for free4/21/2023 In terms of GPS values, 63 patients had a score of 0 or 1, whereas 21 patients had a score of 2. Additionally, the median BMI was 22.0 kg/m2 (range, 14.1-32.8), and the median number of atezolizumab maintenance cycles was 2 (range, 0-24). Most patients had an ECOG performance status of 0 or 1 (83.3%) and stage III or IV SCLC (95.2%). The median patient age was 71 years (range, 43-89). Investigators included a total of 84 patients, of whom 83.3% were male and 16.7% were female. Investigators retrospectively included patients in the analysis if they had cytologically or histologically confirmed SCLC, inoperable stage III/IV disease or postoperative recurrence, and previous treatment with atezolizumab plus carboplatin and etoposide. Patients then received maintenance therapy with atezolizumab every 3 weeks.Įfficacy end points of interest included OS, PFS, and overall response rate (ORR) per RECIST v1.1 criteria. Patients received a fixed dose of 1200 mg of atezolizumab intravenously on day 1 of each cycle plus carboplatin area under the curve of 4 to 5 min/mL intravenously on day 1 and 80 to 100 mg/m 2 of etoposide intravenously on days 1 to 3 of each cycle for 4 to 6 cycles. Investigators of this retrospective study explored several factors that may be predictive of survival outcomes following treatment with atezolizumab plus carboplatin and etoposide, including GPS, neutrophil-to-lymphocyte ratio (NLR), and body mass index (BMI). “Further large-scale analyses are required to examine whether the results of our analysis can be generalized to other SCLC cohorts.” “GPS was identified as a significant predictor after therapy for patients with SCLC,” the study authors stated. Moreover, the median OS in patients with a GPS of 0 or 1 was 16.5 months vs 8.4 months among those with a GPS of 2 ( P <.0001). Patients with a GPS of 0 to 1 had a median PFS of 5.8 months vs 3.8 months for those with a GPS of 2 ( P =. Additionally, a GPS of 0 or 1 correlated with a significantly better PFS. The median PFS and OS from treatment initiation, respectively, were 5.4 months (95% CI, 4.9-5.9) and 15.4 months (95% CI, 11.4-16.8).
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |